
    
      This is a pilot study of Sorafenib combined with Capecitabine in patients with histologically
      confirmed unresectable or metastatic breast and GI tumors. One cycle will consist of 4 weeks
      of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided
      doses. Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14
      days
    
  